Actualización sobre el manejo del síndrome de vejiga urinaria hiperactiva
Artículo de Revisión
Abstract
Abstract: Introduction: Overactive bladder (OAB) syndrome is considered a chronic and disabling condition that is characterized by a series of urinary symptoms, mainly micturition urgency isolated or in combination with urge incontinence plus increased micturition frequency in the absence of another disease. demonstrable. Methodology: A descriptive and retrospective bibliographic review was carried out. To locate bibliographic documents, various documentary sources and guides published by different local and international professional associations of urology are reviewed. An exhaustive search will be followed in repositories and scientific databases such as Pubmed, Scielo, Springer, MedLine, Redalyc, Dialnet, New England Journal of Medicine with the use of descriptors in both English and Spanish. Results: The OAB syndrome circumscribes the urinary symptoms that allow establishing an initial treatment without involving a complex test or method. In particular, urodynamic studies, cystoscopy, and either bladder or renal ultrasound are not recommended as the initial diagnosis of the patient with uncomplicated overactive bladder. In fact, the choice depends on the clinical and therapeutic history of the patient and the clinical judgment of the physician. In some cases, the additional information can guide a different treatment in cases of complicated or refractory patients who have failed multiple treatments. Conclusions: In short, an adequate, timely and updated approach is required for the different managements that involve suffering from overactive urinary bladder syndrome, considering the efficacy, adverse effects, complications and sequelae that each of the treatments can cause.
References
Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF, et al. Reporte de la So-ciedad Internacional de Continencia (ICS): Terminología de la Disfunción Neurogénica del Tracto Urinario Inferior en el Adulto (DNTUIA). Rev Mex Urol. el 20 de mayo de 2022;82(Suplemento):1–19.
Mohmoud MS, Edrees AM, Aly SI, Hospital EST. The Correlation between Overactive Bladder Symptoms and Urodynamic Findings in Men and Women [Internet]. Vol. 87, Cairo Univ. 2019. Disponible en: www.medicaljournalofcairouniversity.net.
Fontaine C, Papworth E, Pascoe J, Hashim H. Update on the management of overactive bladder. Ther Adv Urol. 2021 Aug 31;13:17562872211039034. doi: 10.1177/17562872211039034. PMID: 34484427; PMCID: PMC8411623.
Alkis O, Ozlu A, Kartal IG, Sevim M, Baser A, Aras B. How effectively do we apply first-line treatment in overactive bladder? Int Urogynecol J [Internet]. el 2 de agosto de 2022;33(8):2299–306. Disponible en: https://link.springer.com/10.1007/s00192-022-05279-2.
Yang CF, Huang CY, Wang SY, Chang SR. Prevalence of and Associated Factors for Overactive Bladder Subtypes in Middle-Aged Women: A Cross-Sectional Study. Medicina (Lithuania). el 1 de marzo de 2022;58(3).
Delgado Pacheco M, Siles Luna J, Luksic LT, Duin Ortiz R. Actualización en el diagnóstico y tratamiento del Síndrome de Vejiga Hiperactiva (SVH). 2021;
Scarneciu I, Lupu S, Bratu O, Teodorescu A, Maxim L, Brinza A, et al. Overactive bladder: A re-view and update. Exp Ther Med. el 14 de octubre de 2021;22(6).
Abreu-Mendes P, Portugal-Rodrigues I, Vale L, Dinis P, Cruz F, Antunes-Lopes T, et al. Treat-ment of idiopathic overactive bladder with botulinum toxin: real-life results and patients’ expecta-tions. Porto Biomed J. marzo de 2022;7(2):e164.
Scrivens R. Overactive bladder syndrome: an overview of diagnosis and management. 2022 [ci-tado el 26 de agosto de 2022];118(6). Disponible en: https://cdn.ps.emap.com/wp-content/uploads/sites/3/2022/05/220525-Overactive-bladder-syndrome-an-overview-of-diagnosis-and-management.pdf.
Carrillo-Núñez C, Inés Velazquez-Castellanos P, Godoy-Rodríguez N, Macias-Vera NN. Corre-lation of the bladder wall thickness with overactive bladder syndrome and urodynamic findings Co-rrelación del grosor de la pared vesical con síndrome de vejiga hiperactiva y hallazgos urodinámicos. Artículos originales Revista Mexicana de URología ISSN [Internet]. 2021;81:1–11. Disponible en: https://doi.org/10.48193/rmu.v81i4.598.
Da Mata LRF, Motter PGR, Azevedo C, Bernardes MFVG, Chianca TCM, Vasques CI. Com-plementary therapies in the control of male lower urinary tract symptoms: A systematic review*. Rev Lat Am Enfermagem. 2022;30.
Robinson D, Cardozo L. Managing overactive bladder. Vol. 22, Climacteric. Taylor and Francis Ltd; 2019. p. 250–6.
Scarneciu I, Lupu S, Bratu O, Teodorescu A, Maxim L, Brinza A, et al. Overactive bladder: A review and update. Exp Ther Med. el 14 de octubre de 2021;22(6).
Ann. E, Deborah. J, Kathryin.L, Quentin.J, Culkin.J, Tessier.D. Diagnóstico y Tratamiento de Vejiga Hiperactiva (No Neurogénica) en Adultos: Guía AUA/SUFU. Asociación Urológica Ameri-cana(AUA)/Sociedad de Urodinámica, Medicina Pélvica Femenina y Reconstrucción Urogenital (SUFU). 2019;
Saila O, de Salud D. FARMACOTERAPÉUTICA MANEJO DE LA VEJIGA HIPERACTI-VA. INFAC. 2018;26(10).
Mansfield KJ, Chen Z, Moore KH, Grundy L. Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms. Vol. 13, Frontiers in Physiology. Frontiers Media S.A.; 2022.
Alcántara Montero A, Tovar Matsuki Martín de Prado M. Vibegrón, nuevo agonista selectivo de los receptores beta-3-adrenérgicos, en el tratamiento de la vejiga hiperactiva. Medicina General y de Familia. el 20 de diciembre de 2021;10(6):278–83.
Alcántara Montero A. Novedades en el tratamiento médico de la vejiga hiperactiva. Semergen. el 1 de noviembre de 2016;42(8):557–65.
Bolaños A, Larios C, Ramos Hernandez A, López De Mesa Rodríguez BE, Peralta SR, Noreña L. Experience with Botulinum Toxin in Children with Neurogenic Overactive Bladder: A Case Se-ries. Urologia Colombiana. el 1 de diciembre de 2022;31(4):E149–54.
Marín Martínez FM, Rochell E, Romero B, Javier V, Porcel G, David J, et al. Toxina botulínica intravesical en la vejiga hiperactiva refractaria y repercusión en la calidad de vida [Internet]. Vol. 10, Revista Cubana de Urología. 2021. Disponible en: https://orcid.org/0000-0001-7823-1448PabloLuísGuzmánMartínez-Valls1https://orcid.org/0000-0001-5847-7248.
Kovacic J, Chung A. Busting for change: a care pathway for overactive bladder. Trends in Uro-logy & Men’s Health. julio de 2022;13(4):17–21.
Fandiño G, González S, Eficacia M, Fandiño IG, Soto González M. Eficacia de la estimulación eléctrica del nervio tibial posterior en la vejiga hiperactiva Efficacy of electrical stimulation of the posterior tibial nerve in overactive bladder. Ginecol. 2020;63(1):36–47.
Gerardo LC, Carlos Francisco PB, Alejandra Vianey LD, Jesús RG, Ulises RG, en Gerardo Ló-pez Cruz MC. Neuromodulación transcutánea del nervio tibial posterior como tratamiento no invasi-vo de la incontinencia de orina en niños con discapacidad. Serie de casos [Internet]. Vol. 8, Artículo Original Abril-Junio. 2021. Disponible en: https://www.oaxaca.gob.mx/salud/revista-avance-en-ciencia-salud-y-medicina/.
Casal-Beloy I, García-Novoa MA, Beloy TC, García González M, Somoza Argibay I. Neuroes-timulación eléctrica sacra en la vejiga hiperactiva pediátrica refractaria. An Sist Sanit Navar [Inter-net]. 2020;43(3):417–21. Disponible en: https://doi.org/10.23938/ASSN.879.
Reekmans M, Janssen JMW, Vrijens DMJ, Smits MAC, van Koeveringe GA, van Kerrebroeck PEVA. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients. Neurourol Urodyn. el 1 de junio de 2021;40(5):1120–5.
Tilborghs S, De Wachter S. Sacral neuromodulation for the treatment of overactive bladder: sys-tematic review and future prospects. Expert Rev Med Devices. 2022 Feb;19(2):161-187. doi: 10.1080/17434440.2022.2032655. Epub 2022 Feb 6. PMID: 35061951.
Khasanah N, Chin HY, Peng CW. Physical Agent-Based Treatments for Overactive Bladder: A Review. Vol. 11, Journal of Clinical Medicine. MDPI; 2022.
Wang HJ, Kuo HC. Effects of different urodynamic characteristics on therapeutic outcomes of overactive bladder medication in a real-life clinical practice. Tzu Chi Med J. el 1 de octubre de 2022;34(4):441–7.
Moskowitz D, Adelstein SA, Lucioni A, Lee UJ, Kobashi KC. Use of Third Line Therapy for Overactive Bladder in a Practice with Multiple Subspecialty Providers—Are We Doing Enough? Journal of Urology. el 1 de marzo de 2018;199(3):779–84.
Chun Wei, Jie Gao, Lihua Kou, Xing Liu, Tao Lin, Dawei He. Can Urodynamic Findings of Overactive BladderDetermine the Treatment Effect of Urotherapy in Children? 2020.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is a human-readable summary of (and not a substitute for) the license.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.